ArticleAnnals of medicine2026
High-flow versus standard nasal cannula oxygenation for post-procedural quality of recovery in older adults undergoing sedated ERCP: protocol for a randomized controlled trial.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEndoscopic retrograde cholangiopancreatography (ERCP) in older adults is frequently complicated by intra-procedural desaturation and inflammation, delaying recovery. We compare high-flow nasal cannula (HFNC) oxygenation with standard therapy for improving post-procedural recovery quality and attenuating inflammation. PATIENTS AND
methodsThis single-center, prospective, randomized, patient- and assessor-blinded, parallel-group trial will enroll 106 in-patients aged ≥ 70 years scheduled for elective ERCP under sedation. Following esketamine 0.25 mg/kg and propofol target-controlled infusion (plasma concentration 2.5 µg/mL), patients will be randomly allocated (1:1) to receive either HFNC oxygenation (40 L/min, 100% O DISCUSSION: We hypothesize that HFNC oxygenation will improve 24-h QoR-15 scores, reduce intra-procedural desaturation, and attenuate systemic inflammatory response compared with standard nasal cannula oxygenation. The findings will inform evidence-based respiratory support strategies during ERCP in older adults.
trial registrationChinese Clinical Trial Registry (Identifier: ChiCTR2500105743).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.